Australian Scientists Develop Malaria Drug Giving Near-Lifelong Immunity in Mice
Updated
Updated · thenakedscientists.com · Aug 14
Australian Scientists Develop Malaria Drug Giving Near-Lifelong Immunity in Mice
3 articles · Updated · thenakedscientists.com · Aug 14
Summary
A new anti-malarial drug protected mice from malaria for up to 2 years after a single parasite exposure, with researchers describing near-lifelong immunity in preclinical tests.
The drug works by letting Plasmodium grow in the liver, then killing it just before it enters the bloodstream, preventing symptoms and transmission while triggering strong antibody and CD8 T-cell responses.
Researchers said later mosquito bites could act like natural boosters because the parasite is blocked again at the same liver-stage checkpoint, potentially broadening protection against multiple variants.
The approach targets a gap left by current defenses as mosquitoes resist insecticides, approved vaccines provide limited long-term protection, and parasites keep evolving resistance to existing drugs.
Human studies are still needed, but the team said the drug's roughly 2.5-hour half-life in mice and lasting protection after the drug cleared suggest a potentially game-changing prevention strategy.
Could a new drug turn infectious mosquito bites into natural vaccines without making you sick?
What happens if a liver-stage malaria treatment fails to kill every parasite before they escape?
Turning Mosquito Bites Into Immunity: The 2026 Chemovaccination Breakthrough Against Malaria and Its Global Implications
Overview
In August 2026, researchers introduced a groundbreaking chemovaccination strategy for malaria that combines new drug candidates with controlled exposure to malaria parasites. These drugs block key enzymes, arresting the parasite at the late liver stage and allowing the immune system to recognize more malaria antigens. This triggers a strong, long-lasting immune response with both antibodies and T cells, offering robust protection. However, if drug levels are too low, breakthrough infections can occur. The approach also faces challenges such as allergic reactions to mosquito bites, risks of co-infection with other pathogens, and the need to maintain population immunity to prevent future malaria resurgences.